BioPharmX (BPMX) Misses Q4 EPS by 1c

BioPharmX (NYSE: BPMX) reported Q4 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $35 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on BioPharmX (BPMX) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Exyn Technologies reports Q1 2026 results after Nasdaq IPO
• Nvidia underperforms peers as report sparks rack delay worries